Academic Journal

MedRvix

14 Papers Indexed in Blossom

Published Papers

Open Accessindividual

Molecular, haemodynamic, and functional effects of LSD in the human brain

Using simultaneous PET–MRI in healthy volunteers, this first integrated molecular and functional neuroimaging study quantifies LSD occupancy at cerebral serotonin 2A receptors and establishes a dose–occupancy relationship while revealing an anticlockwise hysteresis between plasma levels and subjective effects. LSD produced distinct haemodynamic and functional changes — increasing global cerebral and internal carotid artery flow without altering artery diameter and reducing global connectivity (GCOR), with GCOR changes negatively correlated with CBF and differing from effects of psilocybin — findings relevant to clinical development.

Published
Journal
MedRvix
Authors
Andersen, T. L., Falck, N., Fisher, P. M., Geisler, M., Holze, F., Jensen, P. S., Johansen, A., Johansen, S. S., Knudsen, G. M., Larsen, K., McCulloch, D. E-W., Neufeld, V., Nielsen, M. K. K., Nykjær, C. H., Randrup, P. P., Reveles Jensen, K. H., Shulganov, V., Skov-Andersen, P., Spanggård, A., Steenstrup, E., Stenbæk, D. S., Svarer, C.
Open Accessindividual

Ketamine treatment effects on DNA methylation and Epigenetic Biomarkers of aging

This preprint open-label study (n=20) examines the effects of ketamine infusions (35mg/70kg, 6x) on biological ageing markers in individuals with depression (MDD) or PTSD. It finds reductions in epigenetic age as measured by OMICmAge, GrimAge V2, and PhenoAge biomarkers, as well as significant changes in Epigenetic Biomarker Proxies (EBPs) and surrogate protein markers following a 2-3 week treatment course. The study also reports expected decreases in depression and PTSD scores as measured by PHQ-9 and PCL-5.

Published
Journal
MedRvix
Authors
Askins, B. C., Carangan, A. M. J. M., Carreras-Gallo, N., Dawson, K., Dawson, M., Dwaraka, V. B., Higgins-Chen, A. T., Klunder, J., Mallin, M., Megilligan, S., Mendez, T. L., Perkins, N., Sehgal, R., Smith, R.
Open Accessindividual

The antidepressant effects of vaporized N,N-Dimethyltryptamine: a preliminary report in treatment-resistant depression

This Phase 2a open‑label, dose‑escalation study in six patients with treatment‑resistant depression found that a single‑day session of vapourised N,N‑dimethyltryptamine produced rapid and sustained reductions in depressive symptoms (mean MADRS change −22 at Day 7 and −17 at one month), with 83.3% response and 66.7% remission at Day 7 and 66.7% response and 50% remission at one month. The authors highlight the non‑invasive, short‑acting delivery as a practical advantage that could improve accessibility of psychedelic-assisted interventional psychiatry.

Published
Journal
MedRvix
Authors
Almeida, R., Araújo, D. B., Arcoverde, E., Arichelle, F., Barbosa, D. C., Barros, H., Bolcont, R., Falchi-Carvalho, M., Florence-Vilela, R., Galvão-Coelho, N. L., Laborde, S., Macedo, R. K. A., Montanini, D., Palhano-Fontes, F., Pantrigo, E. J., Silva, S. R. B., Teixeira, E., Wießner, I.

Quick Facts

Papers Indexed
14
Publisher
Medvix Publications LLC
Website
Visit